QLGN - Qualigen Therapeutics, Inc. EV/EBITDA Multiple

Corporate company logo of Qualigen Therapeutics, Inc. (QLGN)

This chart illustrates that the market value of Qualigen Therapeutics (QLGN) on the GURU.Markets platform is , highlighting a lack of sales for the biotech startup, which relies on issuing new shares to fund its trials. The business focuses on developing nanoparticles to combat oncology and viruses. Supply chain resilience is maintained through the distribution of production capacities, which mitigates risks during medication delivery.

QLGN Qualigen Corp: Business Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/12/2026

Analytical breakdowns for Qualigen Therapeutics

- stock price and consensus target price:
Stock Quotes Qualigen|QLGN - Price Target Chart
- market capitalization statistics:
Market Capitalization Qualigen Corp|QLGN - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Qualigen Therapeutics|QLGN - Accounting Value of Company|Market Cap to Net Assets Ratio qualigeninc.com|QLGN - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Qualigen Therapeutics|QLGN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Qualigen Therapeutics, Inc.|QLGN - Company Total Indebtedness|Debt to Book Value Qualigen Corp|QLGN - Company Long-Term Debts|Company Short-Term Debts Qualigen Therapeutics|Quick Liquidity qualigeninc.com
- business earnings and investment ratios data:
QLGN - Company Net Income|Projected Future Earnings Qualigen Therapeutics|QLGN - Business Payback Period|Forward P/E Multiple Qualigen Therapeutics|QLGN - Price to Net Income Growth Ratio|EV/EBITDA Multiple Qualigen Corp|QLGN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Qualigen Therapeutics|QLGN - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months qualigeninc.com|QLGN - Earnings per share increase in current year|Expected earnings per share growth for next year Qualigen Therapeutics
Basic company analysis:Qualigen (QLGN)
Original product of Qualigen Therapeutics, Inc.

The expansion of the antiviral and oncology pipeline of Qualigen Therapeutics (QLGN) requires significant capital expenditures, making the analysis of debt load critical. The EV/EBITDA value, accounting for total debt, compares the total enterprise value with operating profit before interest, taxes, depreciation, and amortization, stripping the valuation of the influence of the financing structure. A decline in this curve signals that assets are undervalued, while a sharp increase warns that the stock is overbought.

Competitors of Qualigen Therapeutics

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio invivyd.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Enanta Pharmaceuticals, Inc. ENTA|Enterprise Value to EBITDA Multiple Inovio Pharmaceuticals, Inc.|HLVX: Enterprise Value to EBITDA Ratio|KLRS - EV/EBITDA Multiple|DYAI: EV/EBITDA Multiple|NanoViricides (NNVC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Talphera|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COCP|EV/EBITDA Multiple TRAW|Total Company Value to Operating Income Before Depreciation Ratio dwtx.com|EV/EBITDA Multiple ALVR (AlloVir)|Enterprise Value to EBITDA Multiple VBI Vaccines, Inc.|Virios - EV/EBITDA Multiple|Company Value to EBITDA Vaxart, Inc.